3C
VRTX icon

361 Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

361 Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$1.09M Sell
3,750
-565
-13% -$153K 0.51% 25
2020
Q1 		$1.03M Buy
+4,315
New +$990K 0.47% 48

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

361 Capital's VRTX Position: Q2 2020 in Review

361 Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2020, selling an estimated $153K and leaving 3,750 shares worth $1.09M. The position accounts for 0.51% of the portfolio, ranked #25.

361 Capital first reported a position in VRTX in Q1 2020 and has held it in 2 quarters since. 963 funds tracked by Wall St. Rank hold VRTX as of Q2 2020.

  • 361 Capital held 3,750 shares of Vertex Pharmaceuticals worth $1.09M as of Q2 2020.
  • 361 Capital sold 565 Vertex Pharmaceuticals shares in Q2 2020, an estimated $153K.
  • Vertex Pharmaceuticals made up 0.51% of 361 Capital's portfolio in Q2 2020, its #25 holding.
  • 361 Capital first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 2 quarters since.
  • 963 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.